Literature DB >> 21455441

The novelty of research article: Whose responsibility is it?

Ravindra S Beedimani1.   

Abstract

Entities:  

Year:  2011        PMID: 21455441      PMCID: PMC3062141          DOI: 10.4103/0253-7613.75689

Source DB:  PubMed          Journal:  Indian J Pharmacol        ISSN: 0253-7613            Impact factor:   1.200


× No keyword cloud information.
Sir, I would like to comment on the article entitled “Effective control of sickle cell disease with hydroxyurea therapy”[1] published in Jan-Feb, 2010 issue of Indian Journal of Pharmacology. I have found nothing novel about the topic which makes it to be published. Any research article must meet certain criteria and standards that are set by the editorial and review committee before it can be published. That said, I saw nothing novel in the study, the main objective of which was the evaluation of hydroxyurea therapy in sickle cell patients. This has already been well studied and established for some time;[23] indeed, this is referenced in the article itself and in standard pharmacology texts.[45] In the 15 years that I have instructed undergraduate and postgraduate medical students in Pharmacology, I have routinely taught about the effectiveness and safety of hydroxyurea in the control of sickle cell disease. I would therefore enquire the authors and other concerned members about the criteria that merited publication of the article in the journal.
  5 in total

1.  The effect of fetal hemoglobin on the survival characteristics of sickle cells.

Authors:  Robert S Franco; Zahida Yasin; Mary B Palascak; Peter Ciraolo; Clinton H Joiner; Donald L Rucknagel
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

2.  Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease.

Authors:  R E Ware; S A Zimmerman; W H Schultz
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

3.  Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.

Authors:  Vladan P Cokic; Reginald D Smith; Bojana B Beleslin-Cokic; Joyce M Njoroge; Jeffery L Miller; Mark T Gladwin; Alan N Schechter
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

4.  Effective control of sickle cell disease with hydroxyurea therapy.

Authors:  Harminder Singh; Navin Dulhani; Bithika Nel Kumar; Prabhakar Singh; Pawan Tiwari
Journal:  Indian J Pharmacol       Date:  2010-02       Impact factor: 1.200

5.  Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.

Authors:  O S Platt; S H Orkin; G Dover; G P Beardsley; B Miller; D G Nathan
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

  5 in total
  1 in total

1.  Authors' reply.

Authors:  Harminder Singh; Navin Dulhani; Bithika Nel Kumar; Prabhakar Singh; Pawan Tiwari
Journal:  Indian J Pharmacol       Date:  2011-02       Impact factor: 1.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.